Terms: = Lung cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889
69 results:
1. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract] [Full Text] [Related]
2. Unveiling Novel ERCC1-xpf Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design.
Manguinhas R; Serra PA; Soares RB; Rosell R; Gil N; Oliveira NG; Guedes RC
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279246
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic performance of whole-body [
Mirshahvalad SA; Kohan A; Metser U; Hinzpeter R; Ortega C; Farag A; Veit-Haibach P
Eur Radiol; 2024 Jan; 34(1):673-685. PubMed ID: 37535156
[TBL] [Abstract] [Full Text] [Related]
4. Single-nucleotide polymorphisms of nucleotide excision repair genes and their association with overall survival in North Indian lung cancer patients treated with platinum-based doublet chemotherapy.
Singh S; Sharma S; Lawania S; Singh N
J Cancer Res Ther; 2023; 19(2):408-419. PubMed ID: 37006075
[TBL] [Abstract] [Full Text] [Related]
5. Gene network Analysis Defines a Subgroup of Small Cell lung cancer patients With Short Survival.
Cucchiara F; Petrini I; Passaro A; Attili I; Crucitta S; Pardini E; de Marinis F; Danesi R; Del Re M
Clin Lung Cancer; 2022 Sep; 23(6):510-521. PubMed ID: 35739016
[TBL] [Abstract] [Full Text] [Related]
6. A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.
Babu G; Bin Islam S; Khan MA
Mol Biol Rep; 2022 Jul; 49(7):6725-6739. PubMed ID: 35277785
[TBL] [Abstract] [Full Text] [Related]
7. DNA repair and immune checkpoint blockade response.
Guo JA; Alshalalfa M; Kim DY; Hoffman HI; Shiau C; Su J; Hwang WL; Mahal BA
Cancer Genet; 2022 Jun; 264-265():1-4. PubMed ID: 35245846
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell lines.
Suzuki T; Sirimangkalakitti N; Baba A; Toyoshima-Nagasaki R; Enomoto Y; Saito N; Ogasawara Y
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35147203
[TBL] [Abstract] [Full Text] [Related]
9. Contribution of XPD and xpf Polymorphisms to Susceptibility of Non-Small Cell lung cancer in High-Altitude Areas.
Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Li G
Public Health Genomics; 2021; 24(3-4):189-198. PubMed ID: 33827099
[TBL] [Abstract] [Full Text] [Related]
10. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
[TBL] [Abstract] [Full Text] [Related]
11. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/xpf complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
[TBL] [Abstract] [Full Text] [Related]
12. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-xpf-mediated DNA repair.
Ciniero G; Elmenoufy AH; Gentile F; Weinfeld M; Deriu MA; West FG; Tuszynski JA; Dumontet C; Cros-Perrial E; Jordheim LP
Cancer Chemother Pharmacol; 2021 Feb; 87(2):259-267. PubMed ID: 33399940
[TBL] [Abstract] [Full Text] [Related]
13. Nanoparticle-Mediated Gene Silencing for Sensitization of lung cancer to Cisplatin Therapy.
Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
[TBL] [Abstract] [Full Text] [Related]
14. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract] [Full Text] [Related]
15. Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in cancer Patients Assessed for Clinical Trials.
Tiu C; Loh Z; Gan CL; Gan H; John T; Hawkes E
Oncology; 2019; 97(5):270-276. PubMed ID: 31266008
[TBL] [Abstract] [Full Text] [Related]
16. Association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and lung cancer risk in Chinese people: An updated meta-analysis.
Zhong R; Chen Q; Zhang X; Li M; Zhang X; Lin W
Medicine (Baltimore); 2019 Jun; 98(24):e16037. PubMed ID: 31192962
[TBL] [Abstract] [Full Text] [Related]
17. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting xpf to Combat Drug Resistance in lung cancer.
Li C; Li T; Huang L; Yang M; Zhu G
Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
[TBL] [Abstract] [Full Text] [Related]
18. Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in lung cancer.
Heyza JR; Lei W; Watza D; Zhang H; Chen W; Back JB; Schwartz AG; Bepler G; Patrick SM
Clin Cancer Res; 2019 Apr; 25(8):2523-2536. PubMed ID: 30538112
[TBL] [Abstract] [Full Text] [Related]
19. Germline mutations in young non-smoking women with lung adenocarcinoma.
Donner I; Katainen R; Sipilä LJ; Aavikko M; Pukkala E; Aaltonen LA
Lung Cancer; 2018 Aug; 122():76-82. PubMed ID: 30032850
[TBL] [Abstract] [Full Text] [Related]
20. xpf polymorphism toward lung cancer susceptibility and survival in patients treated with platinum-based chemotherapy.
Lawania S; Sharma S; Singh N; Behera D
Future Oncol; 2018 May; 14(11):1071-1089. PubMed ID: 29741112
[TBL] [Abstract] [Full Text] [Related]
[Next]
